Literature DB >> 19381635

Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment.

Valentin Brodszky1, Péter Bálint, Pál Géher, László Hodinka, Gábor Horváth, Éva Koó, Márta Péntek, Anna Polgár, Magdolna Seszták, Sándor Szántó, Ilona Ujfalussy, László Gulácsi.   

Abstract

The objectives of this study were to assess the costs of psoriatic arthritis (PsA) in Hungary and to identify key cost drivers among demographic and clinical variables and to compare cost-of-illness of PsA and rheumatoid arthritis (RA). Cross-sectional retrospective survey of 183 consecutive patients from eight rheumatology centres was conducted. Mean direct medical, direct non medical, indirect and total costs were 1,876, 794, 2,904 and 5,574 euros/patient/year, respectively. Total costs were in significant linear relationship with health assessment questionnaire score and psoriatic area severity index. Costs of RA were higher in all domains than of PsA. Our study was the first from the Eastern European region that provides cost-of-illness data on PsA. Our study revealed that functional status and severity of skin symptoms were the key cost drivers. The costs of PsA in Hungary were lower than in the high-income European countries.

Entities:  

Mesh:

Year:  2009        PMID: 19381635     DOI: 10.1007/s00296-009-0936-1

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  14 in total

1.  Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis.

Authors:  Angela Zink; Katja Thiele; Doerte Huscher; Joachim Listing; Joachim Sieper; Andreas Krause; Erika Gromnica-Ihle; Ulrich von Hinueber; Siegfried Wassenberg; Ekkehard Genth; Matthias Schneider
Journal:  J Rheumatol       Date:  2006-01       Impact factor: 4.666

Review 2.  The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments.

Authors:  G Kobelt; B Jönsson
Journal:  Eur J Health Econ       Date:  2008-01

3.  Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D).

Authors:  N P Hurst; P Kind; D Ruta; M Hunter; A Stubbings
Journal:  Br J Rheumatol       Date:  1997-05

4.  Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.

Authors:  N J Bansback; R Ara; N Barkham; A Brennan; A D Fraser; P Conway; A Reynolds; P Emery
Journal:  Rheumatology (Oxford)       Date:  2006-06-16       Impact factor: 7.580

5.  Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis.

Authors:  S P McKenna; L C Doward; D Whalley; A Tennant; P Emery; D J Veale
Journal:  Ann Rheum Dis       Date:  2004-02       Impact factor: 19.103

6.  Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany.

Authors:  D Huscher; S Merkesdal; K Thiele; H Zeidler; M Schneider; A Zink
Journal:  Ann Rheum Dis       Date:  2006-03-15       Impact factor: 19.103

Review 7.  Economic burden of psoriatic arthritis.

Authors:  Christoph Ackermann; Arthur Kavanaugh
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

8.  The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation.

Authors:  Bonnie Bruce; James F Fries
Journal:  J Rheumatol       Date:  2003-01       Impact factor: 4.666

9.  The direct cost of care for psoriasis and psoriatic arthritis in the United States.

Authors:  Harold S Javitz; Marcia M Ward; Eugene Farber; Lexie Nail; Susan Gillis Vallow
Journal:  J Am Acad Dermatol       Date:  2002-06       Impact factor: 11.527

10.  The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy.

Authors:  I Olivieri; S de Portu; C Salvarani; A Cauli; E Lubrano; A Spadaro; F Cantini; M S Cutro; A Mathieu; M Matucci-Cerinic; N Pappone; L Punzi; R Scarpa; L G Mantovani
Journal:  Rheumatology (Oxford)       Date:  2008-08-24       Impact factor: 7.580

View more
  14 in total

1.  Costs of dementia in Hungary.

Authors:  K Érsek; T Kovács; A Wimo; K Kárpati; V Brodszky; M Péntek; L Jönsson; A Gustavsson; D McDaid; P A Kenigsberg; H Valtonen; L Gulácsi
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

2.  The burden of psoriatic arthritis: a literature review from a global health systems perspective.

Authors:  Seina Lee; Alan Mendelsohn; Evelyn Sarnes
Journal:  P T       Date:  2010-12

3.  Changes in the health status of the population of Central and Eastern European countries between 1990 and 2010.

Authors:  Imre Boncz; Réka Vajda; István Ágoston; Dóra Endrei; Andor Sebestyén
Journal:  Eur J Health Econ       Date:  2014-05-16

Review 4.  Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries.

Authors:  László Gulácsi; Fanni Rencz; Márta Péntek; Valentin Brodszky; Ruth Lopert; Noémi V Hevér; Petra Baji
Journal:  Eur J Health Econ       Date:  2014-05-16

Review 5.  Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries.

Authors:  Márta Péntek; Gyula Poór; Piotr Wiland; Martina Olejárová; Marek Brzosko; Catalin Codreanu; Nóra Brodszky; László Gulácsi
Journal:  Eur J Health Econ       Date:  2014-05-16

Review 6.  EQ-5D studies in musculoskeletal and connective tissue diseases in eight Central and Eastern European countries: a systematic literature review and meta-analysis.

Authors:  Zsombor Zrubka; Fanni Rencz; Jakub Závada; Dominik Golicki; Valentina Prevolnik Rupel; Judit Simon; Valentin Brodszky; Petra Baji; Guenka Petrova; Alexandru Rotar; László Gulácsi; Márta Péntek
Journal:  Rheumatol Int       Date:  2017-08-28       Impact factor: 2.631

7.  Health-related quality of life and utility in patients receiving biological and non-biological treatments in rheumatoid arthritis.

Authors:  András Inotai; Bernadette Rojkovich; Angéla Fülöp; Emese Jászay; Tamás Agh; Agnes Mészáros
Journal:  Rheumatol Int       Date:  2011-01-18       Impact factor: 2.631

8.  Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres.

Authors:  Orsolya Balogh; Valentin Brodszky; László Gulácsi; Emese Herédi; Krisztina Herszényi; Hajnalka Jókai; Sarolta Kárpáti; Petra Baji; Éva Remenyik; Andrea Szegedi; Péter Holló
Journal:  Eur J Health Econ       Date:  2014-05-16

9.  Economic burden of long-term care of rheumatoid arthritis patients in Hungary.

Authors:  Cs Zoltán Horváth; Andor Sebestyén; August Österle; Dóra Endrei; József Betlehem; András Oláh; László Imre; Gabriella Bagosi; Imre Boncz
Journal:  Eur J Health Econ       Date:  2014-05-16

10.  Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics.

Authors:  Michael D Mandel; Mandel D Michael; Anita Bálint; Barbara D Lovász; László Gulácsi; Bálint Strbák; Petra A Golovics; Klaudia Farkas; Zsuzsanna Kürti; Blanka K Szilágyi; Anna Mohás; Tamás Molnár; Péter L Lakatos
Journal:  Eur J Health Econ       Date:  2014-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.